REFERENCES
2. Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study. Clin Genitourin Cancer 2019;17:46-57.e5.
3. Conti A, Santoni M, Sotte V, et al. Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. Urol Oncol 2015;33:303-9.
6. Kaouk JH, Aron M, Rewcastle JC, Gill IS. Cryotherapy: clinical end points and their experimental foundations. Urology 2006;68:38-44.
7. Baust JG, Gage AA, Bjerklund Johansen TE, Baust JM. Mechanisms of cryoablation: clinical consequences on malignant tumors. Cryobiology 2014;68:1-11.
8. Kwak K, Yu B, Lewandowski RJ, Kim DH. Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation. Theranostics 2022;12:2175-204.
9. Breda A, Lam JS, Riggs S, et al. In vivo efficacy of laparoscopic assisted percutaneous renal cryotherapy: evidence based guidelines for the practicing urologist. J Urol 2008;179:333-7.
10. Mues AC, Landman J. Image-guided percutaneous ablation of renal tumors: outcomes, technique, and application in urologic practice. Curr Urol Rep 2010;11:8-14.
11. Rioja J, Tzortzis V, Mamoulakis C, Laguna MP. [Cryotherapy for renal tumors: current status and contemporary developments]. Actas Urol Esp 2010;34:309-17.
12. Buy X, Lang H, Garnon J, Sauleau E, Roy C, Gangi A. Percutaneous renal cryoablation: prospective experience treating 120 consecutive tumors. AJR Am J Roentgenol 2013;201:1353-61.
13. Tsoumakidou G, Buy X, Garnon J, Enescu J, Gangi A. Percutaneous thermal ablation: how to protect the surrounding organs. Tech Vasc Interv Radiol 2011;14:170-6.
14. Hinshaw JL, Lubner MG, Ziemlewicz TJ, Lee FT Jr, Brace CL. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation - what should you use and why? Radiographics 2014;34:1344-62.
15. Seager M, Kumar S, Lim E, Munneke G, Bandula S, Walkden M. Renal cryoablation - a practical guide for interventional radiologists. Br J Radiol 2021;94:20200854.
16. Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol 2021;206:199-208.
17. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022;20:71-90.
18. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 2022;82:399-410.
19. Morris CS, Baerlocher MO, Dariushnia SR, et al. Society of interventional radiology position statement on the role of percutaneous ablation in renal cell carcinoma: endorsed by the canadian association for interventional radiology and the society of interventional oncology. J Vasc Interv Radiol 2020;31:189-194.e3.
20. Janzen N, Zisman A, Pantuck AJ, Perry K, Schulam P, Belldegrun AS. Minimally invasive ablative approaches in the treatment of renal cell carcinoma. Curr Urol Rep 2002;3:13-20.
21. Cantwell CP, Wah TM, Gervais DA, et al. Protecting the ureter during radiofrequency ablation of renal cell cancer: a pilot study of retrograde pyeloperfusion with cooled dextrose 5% in water. J Vasc Interv Radiol 2008;19:1034-40.
22. Rodríguez-Faba O, Palou J, Rosales A, et al. Prospective study of ultrasound-guided percutaneous renal cryotherapy: case selection as an optimization factor for a technique. Actas Urol Esp 2015;39:8-12.
23. Marion JT, Schmitz JJ, Schmit GD, et al. Safety and efficacy of retrograde pyeloperfusion for ureteral protection during renal tumor cryoablation. J Vasc Interv Radiol 2020;31:1249-55.
24. Welch BT, Callstrom MR, Morris JM, et al. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol 2014;192:357-63.
25. Zargar H, Atwell TD, Cadeddu JA, et al. Cryoablation for small renal masses: selection criteria, complications, and functional and oncologic results. Eur Urol 2016;69:116-28.
26. Campbell SC, Uzzo RG, Karam JA, Chang SS, Clark PE, Souter L. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part II. J Urol 2021;206:209-18.
27. Andersen MF, Norus TP. Tumor seeding with renal cell carcinoma after renal biopsy. Urol Case Rep 2016;9:43-4.
28. Macklin PS, Sullivan ME, Tapping CR, et al. Tumour seeding in the tract of percutaneous renal tumour biopsy: a report on seven cases from a UK tertiary referral centre. Eur Urol 2019;75:861-7.
29. Marconi L, Dabestani S, Lam TB, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69:660-73.
30. Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline. J Urol 2017;198:520-9.
31. Allen BC, Remer EM. Percutaneous cryoablation of renal tumors: patient selection, technique, and postprocedural imaging. Radiographics 2010;30:887-900.
33. Tsivian M, Rampersaud EN Jr, del Pilar Laguna Pes M, et al. Small renal mass biopsy - how, what and when: report from an international consensus panel. BJU Int 2014;113:854-63.
34. Truesdale MD, Mues AC, Sartori S, et al. Comparison of two core biopsy techniques before and after laparoscopic cryoablation of small renal cortical neoplasms. JSLS 2011;15:509-16.
35. Guazzoni G, Cestari A, Buffi N, et al. Oncologic results of laparoscopic renal cryoablation for clinical T1a tumors: 8 years of experience in a single institution. Urology 2010;76:624-9.
36. Duffey B, Nguyen V, Lund E, Koopmeiners JS, Hulbert J, Anderson JK. Intermediate-term outcomes after renal cryoablation: results of a multi-institutional study. J Endourol 2012;26:15-20.
37. Guillotreau J, Haber GP, Autorino R, et al. Robotic partial nephrectomy versus laparoscopic cryoablation for the small renal mass. Eur Urol 2012;61:899-904.
38. Okhunov Z, Shapiro EY, Moreira DM, et al. R.E.N.A.L. nephrometry score accurately predicts complications following laparoscopic renal cryoablation. J Urol 2012;188:1796-800.
39. Sidana A, Aggarwal P, Feng Z, Georgiades CS, Trock BJ, Rodriguez R. Complications of renal cryoablation: a single center experience. J Urol 2010;184:42-7.
40. Autorino R, Kaouk JH. Cryoablation for small renal tumors: current status and future perspectives. Urol Oncol 2012;30:S20-7.
41. Zhong J, Bambrook J, Bhambra B, et al. Incidence of post-ablation syndrome following image-guided percutaneous cryoablation of renal cell carcinoma: a prospective study. Cardiovasc Intervent Radiol 2018;41:270-6.
42. Rivoire M, De Cian F, Meeus P, Gignoux B, Fréring B, Kaemmerlen P. Cryosurgery as a means to improve surgical treatment of patients with multiple unresectable liver metastases. Anticancer Res 2000;20:3785-90.
43. Dib R, Touma NJ, Kapoor A. Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. BJU Int 2012;110:510-6.
44. Silverman SG, Israel GM, Trinh QD. Incompletely characterized incidental renal masses: emerging data support conservative management. Radiology 2015;275:28-42.
45. Kotamarti S, Michael Z, Silver D, et al. Device-related complications during renal cryoablation: insights from the manufacturer and user facility device experience (MAUDE) database. Urol Oncol 2022;40:199.e9-199.e14.
46. Breen DJ, Bryant TJ, Abbas A, et al. Percutaneous cryoablation of renal tumours: outcomes from 171 tumours in 147 patients. BJU Int 2013;112:758-65.
47. Tsivian M, Caso J, Kimura M, Polascik TJ. Renal function outcomes after laparoscopic renal cryoablation. J Endourol 2011;25:1287-91.
48. Kim EH, Tanagho YS, Saad NE, Bhayani SB, Figenshau RS. Comparison of laparoscopic and percutaneous cryoablation for treatment of renal masses. Urology 2014;83:1081-7.
49. Laguna MP, Beemster P, Kumar V, et al. Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. Eur Urol 2009;56:355-61.
50. Blute ML Jr, Okhunov Z, Moreira DM, et al. Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications. BJU Int 2013;111:E181-5.
51. Schmit GD, Schenck LA, Thompson RH, et al. Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology 2014;272:903-10.
52. Klatte T, Shariat SF, Remzi M. Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. J Urol 2014;191:1209-17.
53. Lucignani G, Rizzo M, Ierardi AM, et al. Percutaneous microwave ablation is comparable to cryoablation for the treatment of T1a renal masses: results from a cross-sectional study. Clin Genitourin Cancer 2022;20:e506-11.
54. De Cobelli F, Papa M, Panzeri M, et al. Percutaneous microwave ablation versus cryoablation in the treatment of T1a renal tumors. Cardiovasc Intervent Radiol 2020;43:76-83.
55. Nielsen TK, Lagerveld BW, Keeley F, et al. Oncological outcomes and complication rates after laparoscopic-assisted cryoablation: a European registry for renal cryoablation (EuRECA) multi-institutional study. BJU Int 2017;119:390-5.
56. Sisul DM, Liss MA, Palazzi KL, et al. RENAL nephrometry score is associated with complications after renal cryoablation: a multicenter analysis. Urology 2013;81:775-80.
57. Lagerveld BW, Brenninkmeijer M, van der Zee JA, van Haarst EP. Can RENAL and PADUA nephrometry indices predict complications of laparoscopic cryoablation for clinical stage T1 renal tumors? J Endourol 2014;28:464-71.
58. McCafferty BJ, Huang JJ, El Khudari H, et al. External validation of the renal ablation-specific (MC)2 risk scoring system in predicting complications from percutaneous renal cryoablation. Cardiovasc Intervent Radiol 2021;44:1763-8.
59. Papa M, Suardi N, Losa A, et al. ABLATE: a score to predict complications and recurrence rate in percutaneous treatments of renal lesions. Med Oncol 2020;37:26.
60. Deng W, Chen L, Wang Y, et al. Cryoablation versus partial nephrectomy for clinical stage t1 renal masses: a systematic review and meta-analysis. J Cancer 2019;10:1226-36.
61. Chan VW, Abul A, Osman FH, et al. Ablative therapies versus partial nephrectomy for small renal masses - a systematic review and meta-analysis. Int J Surg 2022;97:106194.
62. Beemster PW, Barwari K, Mamoulakis C, Wijkstra H, de la Rosette JJ, Laguna MP. Laparoscopic renal cryoablation using ultrathin 17-gauge cryoprobes: mid-term oncological and functional results. BJU Int 2011;108:577-82.
63. Wehrenberg-Klee E, Clark TW, Malkowicz SB, et al. Impact on renal function of percutaneous thermal ablation of renal masses in patients with preexisting chronic kidney disease. J Vasc Interv Radiol 2012;23:41-5.
64. Sriprasad S, Aldiwani M, Pandian S, et al. Renal function loss after cryoablation of small renal masses in solitary kidneys: european registry for renal cryoablation multi-institutional study. J Endourol 2020;34:233-9.
65. Mitchell CR, Atwell TD, Weisbrod AJ, et al. Renal function outcomes in patients treated with partial nephrectomy versus percutaneous ablation for renal tumors in a solitary kidney. J Urol 2011;186:1786-90.
66. Mues AC, Korets R, Graversen JA, et al. Clinical, pathologic, and functional outcomes after nephron-sparing surgery in patients with a solitary kidney: a multicenter experience. J Endourol 2012;26:1361-6.
67. Uhlig J, Strauss A, Rücker G, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. Eur Radiol 2019;29:1293-307.
68. Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria - a 10-year update. Radiology 2014;273:241-60.
69. Tsivian M, Lyne JC, Mayes JM, Mouraviev V, Kimura M, Polascik TJ. Tumor size and endophytic growth pattern affect recurrence rates after laparoscopic renal cryoablation. Urology 2010;75:307-10.
70. Maxwell AWP, Baird GL, Iannuccilli JD, Mayo-Smith WW, Dupuy DE. Renal cell carcinoma: comparison of RENAL nephrometry and PADUA scores with maximum tumor diameter for prediction of local recurrence after thermal ablation. Radiology 2017;283:590-7.
71. Schmit GD, Thompson RH, Kurup AN, et al. Usefulness of R.E.N.A.L. nephrometry scoring system for predicting outcomes and complications of percutaneous ablation of 751 renal tumors. J Urol 2013;189:30-5.
72. Stacul F, Sachs C, Giudici F, et al. Cryoablation of renal tumors: long-term follow-up from a multicenter experience. Abdom Radiol 2021;46:4476-88.
73. Schmit GD, Atwell TD, Callstrom MR, et al. Percutaneous cryoablation of renal masses [greater than or equal to] 3cm: efficacy and safety in treatment of 108 patients. J Endourol 2010;24:1255-62.
74. Atwell TD, Schmit GD, Boorjian SA, et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol 2013;200:461-6.
75. Aron M, Kamoi K, Remer E, Berger A, Desai M, Gill I. Laparoscopic renal cryoablation: 8-year, single surgeon outcomes. J Urol 2010;183:889-95.
76. Breen DJ, King AJ, Patel N, Lockyer R, Hayes M. Image-guided cryoablation for sporadic renal cell carcinoma: three- and 5-year outcomes in 220 patients with biopsy-proven renal cell carcinoma. Radiology 2018;289:554-61.
77. Thompson RH, Atwell T, Schmit G, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9.
78. Georgiades C, Rodriguez R, Azene E, et al. Determination of the nonlethal margin inside the visible “ice-ball” during percutaneous cryoablation of renal tissue. Cardiovasc Intervent Radiol 2013;36:783-90.
79. Nielsen TK, Vedel PF, Borgbjerg J, Andersen G, Borre M. Renal cryoablation: five- and 10-year survival outcomes in patients with biopsy-proven renal cell carcinoma. Scand J Urol 2020;54:408-12.
80. Ismail M, Nielsen TK, Lagerveld B, et al. Renal cryoablation: multidisciplinary, collaborative and perspective approach. Cryobiology 2018;83:90-4.
81. Tanagho YS, Bhayani SB, Kim EH, Figenshau RS. Renal cryoablation versus robot-assisted partial nephrectomy: Washington University long-term experience. J Endourol 2013;27:1477-86.
82. Martin J, Athreya S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome? Diagn Interv Radiol 2013;19:501-7.
83. Cazalas G, Jambon E, Coussy A, et al. Local recurrence and other oncologic outcomes after percutaneous image-guided tumor ablations on stageT1b renal cell carcinoma: a systematic review and network meta-analysis. Int J Hyperthermia 2021;38:1295-303.
84. Atwell TD, Vlaminck JJ, Boorjian SA, et al. Percutaneous cryoablation of stage T1b renal cell carcinoma: technique considerations, safety, and local tumor control. J Vasc Interv Radiol 2015;26:792-9.
85. Andrews JR, Atwell T, Schmit G, et al. Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2019;76:244-51.
86. Hasegawa T, Yamanaka T, Gobara H, et al. Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study. Jpn J Radiol 2018;36:551-8.
87. Hebbadj S, Cazzato RL, Garnon J, et al. Safety Considerations and local tumor control following percutaneous image-guided cryoablation of T1b renal tumors. Cardiovasc Intervent Radiol 2018;41:449-58.
88. Gunn AJ, Joe WB, Salei A, et al. Percutaneous cryoablation of stage T1b renal cell carcinoma: safety, technical results, and clinical outcomes. Cardiovasc Intervent Radiol 2019;42:970-8.
89. Grange R, Tradi F, Izaaryene J, et al. Computed tomography-guided percutaneous cryoablation of T1b renal tumors: safety, functional and oncological outcomes. Int J Hyperthermia 2019;36:1065-71.
90. Babaian KN, Okhunov Z, Juncal S, et al. Clinical outcomes of patients with nondiagnostic biopsy during cryoablation of small renal masses. Urology 2015;85:605-9.
91. Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol 2009;181:506-11.
92. Powles T, Albiges L, Staehler M, et al. Updated european association of urology guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol 2018;73:311-5.
93. Zondervan PJ, Wagstaff PG, Desai MM, et al. Follow-up after focal therapy in renal masses: an international multidisciplinary Delphi consensus project. World J Urol 2016;34:1657-65.
94. Jiménez JA, Zhang Z, Zhao J, et al. Surgical salvage of thermal ablation failures for renal cell carcinoma. J Urol 2016;195:594-600.
95. Baust JM, Santucci KL, Snyder K, et al. In Vitro Investigation of renal cell carcinoma response to combination sorafenib and cryoablation treatment. clinical oncology and research 2022. Available from: https://www.sciencerepository.org/in-vitro-investigation-of_COR-2022-1-101 [Last accessed on 28 Mar 2023].
96. Liu C, Cao F, Xing W, et al. Efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma. Int J Hyperthermia 2019;36:220-8.
97. Gu CY, Wang JJ, Zhang HL, Shi GH, Ye DW. Survival in metastatic renal cell carcinoma patients treated with sunitinib with or without cryoablation. Front Oncol 2021;11:762547.
98. Campbell MT, Matin SF, Tam AL, et al. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun 2021;12:6375.
99. Lin M, Xu K, Liang S, et al. Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer. Immunol Lett 2017;184:98-104.
100. Harmon TS, Matteo J, Meyer TE, Kee-Sampson J. Pre-cryoablation embolization of renal tumors: decreasing probes and saving loads. Cureus 2018;10:e3676.
101. Matteo J, Loper T, Hood P, Soule E, Kee-Sampson J, Martin JT. Embolization-induced renal tumor shrinkage followed by definitive cryoablation. Cureus 2018;10:e3251.
